Literature DB >> 10088607

Trp-Lys-Tyr-Met-Val-D-Met stimulates superoxide generation and killing of Staphylococcus aureus via phospholipase D activation in human monocytes.

Y S Bae1, S A Ju, J Y Kim, J K Seo, S H Baek, J Y Kwak, B S Kim, P G Suh, S H Ryu.   

Abstract

Among the phagocytic leukocytes, monocytes have the important role of clearing out parasitic microorganisms. They accomplish this through production of toxic metabolites of oxygen. Trp-Lys-Tyr-Met-Val-D-Met (WKYMVm), a peptide that stimulates phosphoinositide (PI) hydrolysis in human leukocytes, including monocytes, binds to a unique cell surface receptor and stimulates superoxide generation, killing of Staphylococcus aureus, and activation of phospholipase D (PLD) in human monocytes. Preincubation of the cells with a PI-specific phospholipase C (PLC) inhibitor (U-73122), protein kinase C inhibitor (GF109203X), or intracellular Ca2+ chelator (BAPTA/AM) before the peptide stimulus totally inhibits the peptide-induced PLD activation and superoxide generation. On the other hand, tyrosine kinase inhibitor genistein only partially inhibits the peptide-induced processes. The peptide-induced bacteria killing activity shares regulatory mechanisms for PLD activation with the superoxide generation, which is inhibited in the presence of 1-butanol. We suggest that the peptide stimulates PLD downstream of PLC activation and PLD activation in turn is essential for the peptide-induced immunological functions such as the superoxide generation and killing of bacteria by human monocytes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10088607     DOI: 10.1002/jlb.65.2.241

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  7 in total

1.  4-1BB (CD137) is required for rapid clearance of Listeria monocytogenes infection.

Authors:  Sang-C Lee; Seong-A Ju; Ha-N Pack; Sook-K Heo; Jae-H Suh; Sang-M Park; Boem-K Choi; Byoung S Kwon; Byung S Kim
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

2.  Selective Display of a Chemoattractant Agonist on Cancer Cells Activates the Formyl Peptide Receptor 1 on Immune Cells.

Authors:  Eden L Sikorski; Janessa Wehr; Noel J Ferraro; Sophia M Rizzo; Marcos M Pires; Damien Thévenin
Journal:  Chembiochem       Date:  2022-03-09       Impact factor: 3.461

Review 3.  Distinct signaling cascades elicited by different formyl peptide receptor 2 (FPR2) agonists.

Authors:  Fabio Cattaneo; Melania Parisi; Rosario Ammendola
Journal:  Int J Mol Sci       Date:  2013-04-02       Impact factor: 5.923

4.  Activation of formyl peptide receptor 2 by WKYMVm enhances emergency granulopoiesis through phospholipase C activity.

Authors:  Hyung Sik Kim; Min Young Park; Sung Kyun Lee; Joon Seong Park; Ha Young Lee; Yoe-Sik Bae
Journal:  BMB Rep       Date:  2018-08       Impact factor: 4.778

Review 5.  Therapeutic potential of WKYMVm in diseases.

Authors:  Huan Ma; Xiaoming Guo; Zhiguo Wang; Mei Han; Hui Liu
Journal:  Front Pharmacol       Date:  2022-09-02       Impact factor: 5.988

6.  The immune-stimulating peptide WKYMVm has therapeutic effects against ulcerative colitis.

Authors:  Sang Doo Kim; Soonil Kwon; Sung Kyun Lee; Minsoo Kook; Ha Young Lee; Ki-Duk Song; Hak-Kyo Lee; Suk-Hwan Baek; Chan Bae Park; Yoe-Sik Bae
Journal:  Exp Mol Med       Date:  2013-09-13       Impact factor: 8.718

7.  Bam32/DAPP1-Dependent Neutrophil Reactive Oxygen Species in WKYMVm-Induced Microvascular Hyperpermeability.

Authors:  Li Hao; Aaron J Marshall; Lixin Liu
Journal:  Front Immunol       Date:  2020-05-27       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.